Technical Analysis for ACOG - Alpha Cognition Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -5.38% | |
| Inside Day | Range Contraction | -5.38% | |
| Gapped Up | Strength | -5.38% | |
| New 52 Week Closing High | Bullish | -6.45% | |
| Gapped Up | Strength | -6.45% |
| Alert | Time |
|---|---|
| Down 3% | about 10 hours ago |
| Down 2 % | about 10 hours ago |
| Rose Above Previous Day's High | about 13 hours ago |
| 2x Volume Pace | about 13 hours ago |
| 1.5x Volume Pace | about 13 hours ago |
Get a Trading Assistant
- Earnings date: Unknown
Alpha Cognition Inc. Description
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.
Classification
Keywords: Biopharmaceutical Alzheimer's Disease Neurodegenerative Diseases Dementia Aging Associated Diseases Cognitive Disorders Treatment Of Alzheimer's Disease Cognitive Impairment Learning Disabilities Alzheimer’s Disease Donepezil
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Date | Title |
|---|---|
| Nov 12 | Alpha Cognition prices $50M stock offering |
| Indicator | Value |
|---|---|
| 52 Week High | 7.0 |
| 52 Week Low | 5.35 |
| Average Volume | 66,233 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 0.00 |
| Average True Range | 0.00 |
| RSI (14) | 0.00 |
| ADX | 0.0 |
| +DI | 0.00 |
| -DI | 0.00 |
| Chandelier Exit (Long, 3 ATRs) | N/A |
| Chandelier Exit (Short, 3 ATRs) | N/A |
| Upper Bollinger Bands | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.08 | ||||
| Resistance 3 (R3) | 6.15 | 5.99 | 5.96 | ||
| Resistance 2 (R2) | 5.99 | 5.81 | 5.95 | 5.92 | |
| Resistance 1 (R1) | 5.68 | 5.70 | 5.60 | 5.61 | 5.88 |
| Pivot Point | 5.51 | 5.51 | 5.47 | 5.48 | 5.51 |
| Support 1 (S1) | 5.20 | 5.33 | 5.12 | 5.13 | 4.86 |
| Support 2 (S2) | 5.04 | 5.22 | 5.00 | 4.82 | |
| Support 3 (S3) | 4.73 | 5.04 | 4.78 | ||
| Support 4 (S4) | 4.66 |
